✦ LIBER ✦

Novel Vasopressin V1A and V2 Antagonist (Conivaptan) Increases Serum Sodium Concentration and Effective Water Clearance in Patients with Hyponatremia

✍ Scribed by Joseph G. Verbalis; Joseph G. Bisaha; Neila Smith

Book ID: 119212220
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 58 KB
Volume: 10
Category: Article
ISSN: 1532-8414
DOI: 10.1016/j.cardfail.2004.06.033

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Novel Vasopressin V1A and V2 Antagonist

Novel Vasopressin V1A and V2 Antagonist (Conivaptan) Increased Serum Sodium Concentration in Patients with Hyponatremia Secondary to Congestive Heart Failure

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Acute hemodynamic effects of conivaptan,

Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure

✍ J.E. Udelson; W.B. Smith; G.H. Hendrix 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 33 KB

Effects of satavaptan, a selective vasop

Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial

✍ Pere Ginès; Florence Wong; Hugh Watson; Slobodan Milutinovic; Luis Ruiz del Arbo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

Hyponatremia in cirrhosis is associated with significant morbidity and mortality and complicates ascites management. Vasopressin receptor antagonists improve serum sodium concentration by increasing renal solute-free water excretion, but their effects on the management of ascites have not been asses

Pharmacokinetics of conivaptan hydrochlo

Pharmacokinetics of conivaptan hydrochloride, a vasopressin V1A/V2-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study

✍ Zhongping Lily Mao; Dennis Stalker; James Keirns 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 866 KB

Cardiovascular and renal effects of coni

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure

✍ Takeyuki Yatsu; Yuichi Tomura; Atsuo Tahara; Koh-ichi Wada; Toshiyuki Kusayama; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 466 KB

732 Effects of satavaptan (SR121463B), a

732 Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia

✍ P. Gines; F. Wong; S. Milutinovic; L. Ruiz del Arbol; D. Olteanu 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 114 KB